Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

26.86 -1.13 (-4.04%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,548,719
Open	27.77
Bid (Size)	26.25 (300)
Ask (Size)	27.38 (100)
Prev. Close	27.99
Today's Range	26.32 - 27.96
52wk Range	13.70 - 31.77
Shares Outstanding	50,241,789
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗

July 23, 2026

Via Chartmill

Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗

July 20, 2026

Via Chartmill

Performance

YTD	-7.4%	-7.4%
1 Month	+4.1%	+4.1%
3 Month	+14.3%	+14.3%
6 Month	+5.0%	+5.0%
1 Year	+88.0%	+88.0%

More News

Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗

July 17, 2026

Via Chartmill

Arcutis Expands Board of Directors with Appointment of Chris Peetz

July 16, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

July 08, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗

June 23, 2026

Via The Motley Fool

Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗

June 22, 2026

Via Chartmill

Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗

May 06, 2026

Via Chartmill

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗

July 03, 2026

Via The Motley Fool

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

June 30, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

June 29, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗

June 09, 2026

Via MarketBeat

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

Via The Motley Fool

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

June 03, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis (ARQT) Q1 2026 Earnings Transcript ↗

May 07, 2026

Via The Motley Fool

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

April 27, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

April 22, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate ↗

April 14, 2026

Via Chartmill

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know ↗

April 08, 2026

Via The Motley Fool

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

April 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

March 28, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

March 18, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

March 10, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

March 05, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?

Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.

What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?

Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?

The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market

What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?

The current price of Arcutis Biotherapeutics, Inc. - Common stock is 26.86

When was Arcutis Biotherapeutics, Inc. - Common stock last traded?

The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 07/31/26 04:00 PM ET

What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?

The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.35B

How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?

Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.